Legacy Wealth Management LLC MS purchased a new position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm purchased 19,427 shares of the medical research company's stock, valued at approximately $3,425,000. IQVIA comprises approximately 1.1% of Legacy Wealth Management LLC MS's investment portfolio, making the stock its 21st largest position.
Other hedge funds and other institutional investors have also made changes to their positions in the company. JPMorgan Chase & Co. boosted its stake in IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company's stock worth $437,378,000 after acquiring an additional 583,396 shares during the last quarter. Janney Montgomery Scott LLC boosted its position in shares of IQVIA by 3.3% during the fourth quarter. Janney Montgomery Scott LLC now owns 36,512 shares of the medical research company's stock worth $7,175,000 after purchasing an additional 1,172 shares in the last quarter. Mutual Advisors LLC lifted its holdings in IQVIA by 14.8% during the fourth quarter. Mutual Advisors LLC now owns 1,689 shares of the medical research company's stock worth $334,000 after acquiring an additional 218 shares in the last quarter. Brighton Jones LLC lifted its holdings in shares of IQVIA by 244.4% during the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company's stock valued at $703,000 after purchasing an additional 2,537 shares in the last quarter. Finally, Exchange Traded Concepts LLC lifted its stake in IQVIA by 18.7% in the fourth quarter. Exchange Traded Concepts LLC now owns 5,209 shares of the medical research company's stock valued at $1,024,000 after buying an additional 821 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
IQV has been the topic of a number of research reports. Redburn Partners set a $188.00 price target on shares of IQVIA in a research note on Friday, May 23rd. Robert W. Baird cut their price target on IQVIA from $195.00 to $161.00 and set a "neutral" rating on the stock in a report on Wednesday, May 7th. Hsbc Global Res lowered IQVIA from a "strong-buy" rating to a "hold" rating in a report on Friday, April 25th. Mizuho cut their target price on IQVIA from $210.00 to $190.00 and set an "outperform" rating on the stock in a research note on Thursday, May 15th. Finally, Barclays cut their target price on IQVIA from $170.00 to $165.00 and set an "equal weight" rating on the stock in a research note on Wednesday, May 7th. Eight investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $226.32.
Read Our Latest Report on IQVIA
IQVIA Stock Performance
NYSE:IQV traded down $0.86 on Friday, hitting $140.16. The company's stock had a trading volume of 2,874,682 shares, compared to its average volume of 1,577,820. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $252.88. The stock has a fifty day moving average of $150.79 and a two-hundred day moving average of $180.93. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm has a market capitalization of $24.25 billion, a P/E ratio of 18.69, a price-to-earnings-growth ratio of 1.99 and a beta of 1.34.
IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, beating analysts' consensus estimates of $2.63 by $0.07. The business had revenue of $3.83 billion for the quarter, compared to analysts' expectations of $3.77 billion. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The firm's revenue for the quarter was up 2.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.54 EPS. Research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.
About IQVIA
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Stories
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
